Schoenberg Mark's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Sep 12, 2024
- Accession no.
- 0001437749-24-029040
- Filed
- Sep 12, 2024
- Trade date
- Sep 9, 2024
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $11.2K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Ordinary Shares | MOption exerciseAcquired | +1,666 | –F1 | – | 145,950 | Direct | |
| Sep 9, 2024 | Ordinary Shares | SSaleDisposed | −859 | $13.08 | −$11,235.72 | 145,091 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Ordinary Shares | MOption exerciseDisposed | −1,666 | $0.00 | $0 | 3,334 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Referenced by the price of 1 transaction in Table I.